A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Public ClinicalTrials.gov record NCT06447662. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene
Study identification
- NCT ID
- NCT06447662
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 330 participants
Conditions and interventions
Interventions
- Bevacizumab Combination Product
- Carboplatin Combination Product
- Cetuximab Combination Product
- Cisplatin Combination Product
- Fluorouracil Combination Product
- Gemcitabine Combination Product
- Leucovorin Combination Product
- Nab-paclitaxel Combination Product
- Oxaliplatin Combination Product
- PF-07934040 Drug
- Paclitaxel Combination Product
- Pembrolizumab Combination Product
- Sasanlimab Combination Product
- pemetrexed Combination Product
Combination Product · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 26, 2024
- Primary completion
- Jan 18, 2028
- Completion
- Jan 17, 2029
- Last update posted
- Apr 19, 2026
2024 – 2029
United States locations
- U.S. sites
- 26
- U.S. states
- 10
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group, PA | Fayetteville | Arkansas | 72703 | Recruiting |
| Highlands Oncology Group, PA | Rogers | Arkansas | 72758 | Recruiting |
| Highlands Oncology Group | Springdale | Arkansas | 72762 | Recruiting |
| City of Hope (City of Hope National Medical Center, City of Hope Medical Center) | Duarte | California | 91010 | Recruiting |
| City of Hope Investigational Drug Service (IDS) | Duarte | California | 91010 | Recruiting |
| University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) | Aurora | Colorado | 80045 | Recruiting |
| University of Colorado Hospital - Anschutz Outpatient Pavilion | Aurora | Colorado | 80045 | Recruiting |
| University of Colorado Hospital- Anschutz Cancer Pavilion (ACP) | Aurora | Colorado | 80045 | Recruiting |
| University of Colorado Hospital | Aurora | Colorado | 80045 | Recruiting |
| Sibley Memorial Hospital | Washington D.C. | District of Columbia | 20016 | Recruiting |
| START Midwest | Grand Rapids | Michigan | 49546 | Recruiting |
| Siteman Cancer Center - St Peters | City of Saint Peters | Missouri | 63376 | Recruiting |
| Siteman Cancer Center - West County | Creve Coeur | Missouri | 63141 | Recruiting |
| Siteman Cancer Center - North County | Florissant | Missouri | 63031 | Recruiting |
| Siteman Cancer Center | St Louis | Missouri | 63108 | Recruiting |
| Barnes-Jewish Hospital | St Louis | Missouri | 63110 | Recruiting |
| Washington University School of Medicine | St Louis | Missouri | 63110 | Recruiting |
| Siteman Cancer Center - South County | St Louis | Missouri | 63129 | Recruiting |
| Duke University Medical Center, lnvestigational Chemotherapy Service | Durham | North Carolina | 27710 | Recruiting |
| Duke University Medical Center | Durham | North Carolina | 27710 | Recruiting |
| University of Cincinnati Medical Center | Cincinnati | Ohio | 45219 | Recruiting |
| Cleveland Clinic Taussig Cancer Center | Cleveland | Ohio | 44195 | Recruiting |
| West Chester Hospital | West Chester | Ohio | 45069 | Recruiting |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | Recruiting |
| Miriam Hospital | Providence | Rhode Island | 02906 | Recruiting |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06447662, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 19, 2026 · Synced May 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06447662 live on ClinicalTrials.gov.